香港股市 已收市

Becton, Dickinson and Company (BDX)

NYSE - NYSE 延遲價格。貨幣為 USD。
加入追蹤清單
247.45+0.92 (+0.37%)
收市:04:00PM EDT
246.50 -0.95 (-0.38%)
收市後: 06:10PM EDT
全螢幕
交易股價資料並非來自所有市場
前收市價246.53
開市246.73
買盤247.71 x 800
賣出價247.80 x 900
今日波幅245.33 - 248.42
52 週波幅229.86 - 287.32
成交量994,158
平均成交量1,472,524
市值71.489B
Beta 值 (5 年,每月)0.44
市盈率 (最近 12 個月)56.50
每股盈利 (最近 12 個月)4.38
業績公佈日2024年5月02日 - 2024年5月06日
遠期股息及收益率3.80 (1.54%)
除息日2024年3月07日
1 年預測目標價278.54
  • Zacks

    Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

    The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

  • Zacks

    QIAGEN (QGEN) Partners With IPPA to Raise TB Screening Awareness

    QIAGEN's (QGEN) collaboration with IPPA follows the updated CDC guidelines for TB screening for immigrants in the United States.

  • Reuters

    UPDATE 3-Becton Dickinson ramps up syringe production in US amid China quality concerns

    Becton Dickinson said on Thursday it has increased production of medical syringes in the United States after the country's drug regulator recommended not using some China-made syringes as part of its ongoing quality probe. The U.S.-based medical equipment maker — one of the world's largest syringe suppliers — said it had increased manufacturing in its Nebraska and Connecticut facilities, since the U.S. Food and Drug Administration first raised concerns about China-made syringes in November. The FDA had said last year it was looking into reports of leaks, breakages and other quality problems with plastic syringes manufactured in China and that it may prevent such syringes from entering the U.S. market, if necessary.